Eforto
Eforto is the muscle fatigability biomarker for GLP-1 trials. With up to 40% of incretin-induced weight loss being lean mass, sponsors need functional evidence beyond imaging. Eforto’s validated digital vigorimeter measures muscle strength and fatigability (grip work) at home, with a validated 5-minute test-protocol, generating frequent functional data across the full trial timeline. Validated in cohorts, FDA-listed, and API-ready for EDC integration. While DXA and MRI visualize structure, Eforto provides the necessary functional evidence: confirming muscle performance rather than just mass.
